The Medical Research Council has invested £50 million in a new centre aimed at improving treatment for mitochondrial diseases, one of the most challenging groups of inherited disorders in modern medicine. Announced on 5 August 2026, the Centre of Research Excellence in Mitochondrial Genome Therapeutics will bring together specialists from multiple disciplines to understand how mutations in mitochondrial DNA cause disease and to turn that knowledge into therapies.
A major UK effort focused on a rare but devastating condition
Mitochondrial diseases affect around one in 5,000 people, and there is currently no cure, according to the MRC. The council said the condition leaves patients and families facing significant unmet medical needs, while mitochondrial DNA mutations are also increasingly linked to neurodegeneration, metabolic disease, cardiovascular failure and age-related deterioration.
In affected individuals, mitochondrial dysfunction can contribute to severe disability, progressive decline and premature death. The new centre is designed to address that gap by building scientific foundations for entirely new therapeutic strategies.
Researchers say the project could reshape the field
Project lead Professor Michal Minczuk of the University of Cambridge said the centre will provide approaches to understanding and treating diseases caused by mutations in the mitochondrial genome. He said the team aims to build a long-term UK research platform with the scale, expertise and infrastructure needed to position the UK as a global leader in mitochondrial genome therapeutics.
The centre will also use emerging technologies to engineer the mitochondrial genome and develop advanced models of pathogenic mtDNA mutations. It will be led by the University of Cambridge and partner with the University of Birmingham, The University of Manchester, Heidelberg University, the University of Queensland and the Imagine Institute in Paris. The MRC said it will also work with charities including the Lily Foundation and industry partners worldwide.
Building on earlier UK progress in mitochondrial science
Dr Ceri Williams, Executive Director of Challenge Led Themes at the MRC, said the UK has already led the development of mitochondrial replacement therapy, which prevents the inheritance of mtDNA mutations. She said the new centre builds on that foundation and brings together expertise from around the world and across sectors to make progress on the root causes of mtDNA mutations.
Williams added that the interdisciplinary approach could transform health research in this field by improving prevention, detection and treatment, and by boosting outcomes for patients and families affected by the disease. The Lily Foundation said its role as a patient charity partner will help ensure family priorities shape the research from the outset.
The new funding marks one of the latest major UK research investments in rare disease science, with the MRC presenting the initiative as a long-term platform for translational progress. For patients living with mitochondrial disease, the centre represents renewed hope that laboratory advances may eventually lead to meaningful treatment options.
Source: UKRI / MRC news
Photo source: AI-generated or edited image
